

Image



Patent  
Attorney's Docket No. 034074-685

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
James E. Audia	)	Group Art Unit: 1624
Application No.: 09/882,777	)	Examiner: Bruck Kifle
Filed: June 14, 2001	)	Confirmation No.: 1280
For: Polycyclic A-Amineo-ε Caprolactams and Related Compounds	)	

**SUPPLEMENTAL COMMUNICATION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The referenced application is now under a Notice of Allowance. During applicants' post-allowance audit of the file, we have discovered that applicants have not received an acknowledgement of the Information Disclosure Statement filed on September 10, 2001. As a result, applicants do not have any record confirming that the Information Disclosure Statement was received by the Examiner and that the cited references were considered. During a telephone conversation with Examiner Kifle of March 17, 2004, he confirmed that the IDS had been received and considered, and agreed to provide applicants with an Examiner-initialed copy of that PTO-1449 form, and suggested applicants file this Supplemental Communication to facilitate that acknowledgement. Accordingly, applicants hereby request that the U.S. Patent and Trademark Office provide an acknowledgement in the form of an Examiner-initialed copy of that Information Disclosure Statement at the earliest opportunity.


If the Examiner has any questions or comments regarding this request, applicants encourage the Examiner to contact their representative at the number provided below.

Respectfully submitted,


BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: March 17, 2004

By:

  
Brian P. O'Shaughnessy  
Registration No. 32,747

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620



# INFORMATION DISCLOSURE CITATION

PTO-1449

ATTORNEY'S DKT NO.  
002010-685APPLICATION NO.  
09/882,777APPLICANT  
Audia, et al.FILING DATE  
June 14, 2001GROUP  
1624

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	3,598,859	8/10/71	Yates, et al.			
	3,657,341	4/18/72	Thorne			
	4,080,449	3/21/78	Croisier, et al.			
	4,477,464	10/16/84	Slade, et al.			
	4,666,829	5/19/87	Glenner, et al.			
	4,977,168	12/11/90	Bernat, et al.			
	5,238,932	8/24/93	Flynn, et al.			
	5,283,241	2/1/94	Bochis, et al.			
	5,284,841	2/8/94	Chu, et al.			
	5,324,726	6/28/94	Bock, et al.			
	5,360,802	11/1/94	Chambers, et al.			
	5,420,271	5/30/95	Warshawsky, et al.			
	5,478,857	12/26/95	Clemens, et al.			
	5,556,969	9/17/96	Chambers, et al.			
	5,633,251	5/27/97	Claremon, et al.			
	5,658,901	8/19/97	Claremon, et al.			
	5,712,397	1/27/98	Esser, et al.			
	5,770,573	6/23/98	Arrhenius, et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
	0 061 187	9/29/82	Europe				
	0 167 919	1/15/86	Europe				
	0 284 256	9/28/88	Europe				
	0 349 949	1/10/90	Europe				
	0 376 849	7/4/90	Europe (Abstract in English)				

COPY

# INFORMATION DISCLOSURE CITATION

PTO-1449

ATTORNEY'S DKT NO.  
002010-685APPLICATION NO.  
09/882,777APPLICANT  
Audia, et al.FILING DATE  
June 14, 2001GROUP  
1624

0 434 360	6/26/91	Europe				
0 434 364	6/26/91	Europe				
0 434 369	6/26/91	Europe				
0 490 590	6/17/92	Europe				
0 514 133	11/19/92	Europe				
0 523 845	1/20/93	Europe				
0 549 039	6/30/93	Europe				
0 647 632	4/12/95	Europe				
0 652 009	8/16/95	Europe				
0 667 344	8/16/95	Europe (Abstract in English)				
0 677 517	10/18/95	Europe				
0 732 399	9/18/96	Europe				
0 778 266	11/6/97	Europe				
1 519 495	7/6/78	Great Britain				
1 573 931	8/18/80	Great Britain				
2 272 439	5/18/94	Great Britain				
2 290 788	1/10/96	Great Britain				
04210967	8/3/94	Japan (Abstract in English)				
06145148	5/24/94	Japan (Abstract in English)				
07304770	11/21/95	Japan (Abstract in English)				
10072444	3/17/98	Japan (Abstract in English)				
92/01683	2/6/92	WIPO				
92/16524	10/1/92	WIPO				
93/19052	9/30/93	WIPO				
93/19063	9/30/93	WIPO				
94/05693	3/17/94	WIPO				
94/04531	3/3/94	WIPO				
94/07486	4/14/94	WIPO				
94/10569	5/11/94	WIPO				

COPY

# INFORMATION DISCLOSURE CITATION

PTO-1449

ATTORNEY'S DKT NO.  
002010-685APPLICATION NO.  
09/882,777APPLICANT  
Audia, et al.FILING DATE  
June 14, 2001GROUP  
1624

	95/03289	2/2/95	WIPO				
	95/03290	2/2/95	WIPO				
	95/09838	4/13/95	WIPO				
	95/14671	6/1/95	WIPO				
	95/21840	8/17/95	WIPO				
	95/23810	9/8/95	WIPO				
	95/25118	9/21/95	WIPO				
	95/32191	11/30/95	WIPO				
	96/05839	2/29/96	WIPO				
	96/16981	6/6/96	WIPO				
	96/20725	7/11/96	WIPO				
	96/22966	8/1/96	WIPO				
	96/40146	12/19/96	WIPO				
	96/40653	12/19/96	WIPO				
	96/40654	12/19/96	WIPO				
	96/40655	12/19/96	WIPO				
	96/40656	12/19/96	WIPO				
	97/30072	8/21/97	WIPO				
	97/38705	10/23/97	WIPO				
	98/00405	1/8/98	WIPO				
	98/25930	6/18/98	WIPO				
	98/28268	7/2/98	WIPO				
	98/38177	9/3/98	WIPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Aquino, et al. "Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist "Trigger." *J. Med. Chem.* 39: 562-569 (1996).

COPY

# INFORMATION DISCLOSURE CITATION

PTO-1449

ATTORNEY'S DKT NO.  
002010-685APPLICATION NO.  
09/882,777APPLICANT  
Audia, et al.FILING DATE  
June 14, 2001GROUP  
1624

- Bock, et al. "Selective Non-Peptide Ligands for an Accommodating Peptide Receptor. Imidazobenzodiazepines as Potent Cholecystokinin Type B Receptor Antagonists." *Bioorg. and Med. Chem. Lett.* 2(9):987-998 (1994).
- Bock, et al. "Synthesis and Resolution of 3-Amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones." *J. Org. Chem.* 52: 3232-3239 (1987).
- Bock, et al. "An Expedient Synthesis of 3-Amino-1,3-Dihydro-5-Phenyl-2H-1,4-Benzodiazepin-2-one." *Tet. Lett.* 28(9): 939-942 (1987).
- Chambers, et al. L-708,474: the C5-Cyclohexyl Analogue of L-365,260, A Selective High Affinity Ligand for the CCKB/Gastrin Receptor." *Bioorg. and Med. Chem. Letts.* 3(10):1919-1924 (1993).
- Chartier-Harlin, et al. "Early-onset Alzheimer's disease caused by mutations at codon 717 of the  $\beta$ -Amyloid precursor protein gene." *Nature.* 353: 844-846 (1991).
- Citron, et al. "Mutation of the  $\beta$ -amyloid precursor protein in familial Alzheimer's disease increases  $\beta$ -amyloid protein production." *Nature* 360:672-674 (1992).
- Cordell. "B-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease." *Ann. Rev. Pharmacol. Toxicol.* 34:69-89 (1994).
- Evans, et al. "Methods for Drug Discovery: Development of Potent, Selective Orally Effective Cholecystokinin Antagonists." *J. Med. Chem.* 31:2235-2246 (1988).
- Evans, et al. "Molecular Mimicry and the Design of Peptidomimetics." *Molecular Mimicry in Health and Disease.* (A. Lernmark, et al., eds.) Elsevier Science Publishers B.v. (Biomedical Division) (1988) pp. 23-34.
- Finizia, et al. "Synthesis and Evaluation of Novel 1,5-Benzodiazepines as potent and selective CCK-B Ligands, Effect of the Substitution of the N-5 Phenyl with Alkyl Groups." *Bioorg. & Medicinal Chemistry Letters.* 6(24):2957-2962 (1996).
- Glennner, et al. "Alzheimer's disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein." *Biochem. Biophys. Res. Commun.* 120(3): 885-890 (1984).
- Goate, et al. "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease." *Nature.* 349: 704-706 (1991).
- Hirst, et al. "Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonists Activity (II): Optimization of the C3 Amino Substituent." *J. Med. Chem.* 39: 5236-5245 (1996).
- Hofmann, et al. "Interactions of Benzodiazepine Derivatives with Annexins." *J. Biol. Chem.* 273(5):2885-2894 (1998).
- Johnson-Wood, et al. "Amyloid precursor protein processing and  $A\beta_{42}$  deposition in a transgenic mouse model of Alzheimer's disease." *PNAS USA.* 94: 1550-1555 (1997).
- Ksander, G.M., et al. "Dual Angiotensin Converting Enzyme/Thromboxane Synthase Inhibitors." *J. Med. Chem.* 37: 1823-1832 (1994).
- Lowe, et al. "A Water Soluble Benzazepine Cholecystokinin-B-Receptor Antagonist." *Bioorg. and Med. Chem. Lett.* 5(17): 1933-1936 (1995).
- Lowe, et al. "5-Phenyl-3-ureidobenzazepin-2-ones as Cholecystokinin-B Receptor Antagonists." *J. Med. Chem.* 37: 3789-3811 (1994).

COPY

# INFORMATION DISCLOSURE CITATION

 ATTORNEY'S DKT NO.  
002010-685


 APPLICATION NO.  
09/882,777

 APPLICANT  
Audia, et al.

 FILING DATE  
June 14, 2001

 GROUP  
1624

PTO-1449



	Mullan, et al. "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of $\beta$ -amyloid." <i>Nature Genet.</i> 1: 345-347 (1992).
	Murrell, et al. "A Mutation in the Amyloid Precursor Protein Associate with Hereditary Alzheimer's Disease." <i>Science.</i> 254: 97-99 (1991).
	Papadopoulos, et al. Anodic Oxidation of N-Acyl and N-Alkoxy carbonyl Dipeptide Esters as a Key Step for the Formation of Chiral Heterocyclic Synthetic Building Blocks." <i>Tetrahedron</i> 47(4/5):563-572 (1991).
	Patel, et al. "Biological Properties of the Benzodiazepine Amidine Derivative L-740,093, a Cholecystokinin-B/Gastrin Receptor Antagonist with High Affinity in vitro and High Potency in vivo." <i>Molecular Pharmacology.</i> 46:943-948 (1994).
	Rittle, et al. "A New Amine Resolution Method and its Application to 3-Aminobenzodiazepines." <i>Tet. Lett.</i> 28(5):521-522 (1987).
	Satoh, et al. "New 1,4-Benzodiazepine-2-one Derivatives as Gastrin/Cholecystokinin-B Antagonists." <i>Chem. Pharm. Bull.</i> 43(12): 2159-2167 (1995).
	Selkoe, et al. "Amyloid Protein and Alzheimer's Disease." <i>Scientific American.</i> 68-78 (1991).
	Selkoe, et al. "The Molecular Pathology of Alzheimer's Disease." <i>Neuron.</i> 6:487-498 (1991).
	Semple, et al. "Design, Synthesis, and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1-Argininal Derivatives Incorporating P3-P4 Lactam Sulfoamide Moieties." <i>J. Med. Chem.</i> 39: 4531-4536 (1996).
	Semple, et al. "A Facile Large Scale Synthesis of Optically Active 3-Amino-5-(2-Pyridyl)-1,4-Benzodiazepin-2-One Derivatives." <i>Synthetic Communications.</i> 26(4): 721-727 (1996).
	Seubert, et al. "Isolation and quantification of soluble Alzheimer's peptide from biological fluids." <i>Nature.</i> 359: 325-327 (1992).
	Sherrill, et al. "An Improved Synthesis and Resolution of 3-Amino-1,3 dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones." <i>J. Org. Chem.</i> 60:730-734 (1995).
	Showell, et al. "High Affinity and Potent, Water-Soluble 5-Amino-1,4-Benzodiazepine CCKB/Gastrin Receptor Antagonists Containing a Cationic Solubilizing Group." <i>J. Med. Chem.</i> 37:719-721 (1994).
	Smith, et al. " $\beta$ -APP Processing as a Therapeutic Target for Alzheimer's Disease." <i>Current Pharmaceutical Design.</i> 3:439-445 (1997).
	Van Niel, et al. "CCKB Selective Receptor Ligands: Novel 1,3,5-Trisubstituted Benzazepin-2-ones." <i>Bioorganic &amp; Medicinal Chemistry Letters.</i> 5(13):1421-1426 (1995).
	Varnavas, et al. "Synthesis of New Benzodiazepine Derivatives as Potential Cholecystokinin Antagonists." <i>Il Farmaco.</i> 46(2):391-401 (1991).
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY